DE60201859D1 - Pharmazeutische Verwendung von N-Carbamoylazol-Derivate - Google Patents

Pharmazeutische Verwendung von N-Carbamoylazol-Derivate

Info

Publication number
DE60201859D1
DE60201859D1 DE60201859T DE60201859T DE60201859D1 DE 60201859 D1 DE60201859 D1 DE 60201859D1 DE 60201859 T DE60201859 T DE 60201859T DE 60201859 T DE60201859 T DE 60201859T DE 60201859 D1 DE60201859 D1 DE 60201859D1
Authority
DE
Germany
Prior art keywords
carbamoylazole
derivatives
pharmaceutical use
pharmaceutical
carbamoylazole derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60201859T
Other languages
English (en)
Other versions
DE60201859T2 (de
Inventor
Nobuyuki Yasuda
Tadashi Nagakura
Kazuto Yamazaki
Seiji Yoshikawa
Toshimi Okada
Hironori Ikuta
Mika Koyanagi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DE60201859D1 publication Critical patent/DE60201859D1/de
Publication of DE60201859T2 publication Critical patent/DE60201859T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60201859T 2001-05-18 2002-05-17 Pharmazeutische Verwendung von N-Carbamoylazol-Derivate Expired - Lifetime DE60201859T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001149983 2001-05-18
JP2001149983 2001-05-18

Publications (2)

Publication Number Publication Date
DE60201859D1 true DE60201859D1 (de) 2004-12-16
DE60201859T2 DE60201859T2 (de) 2005-10-20

Family

ID=18995082

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60201859T Expired - Lifetime DE60201859T2 (de) 2001-05-18 2002-05-17 Pharmazeutische Verwendung von N-Carbamoylazol-Derivate

Country Status (4)

Country Link
US (2) US20030060494A1 (de)
EP (1) EP1258480B1 (de)
DE (1) DE60201859T2 (de)
ES (1) ES2231609T3 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4371295B2 (ja) * 2000-05-19 2009-11-25 メルク セローノ ソシエテ アノニム 医薬として活性な化合物およびその使用方法
DE60222667T2 (de) 2001-06-27 2008-07-17 Smithkline Beecham Corp. Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren
CA2518465A1 (en) 2003-03-25 2004-10-14 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US7678909B1 (en) 2003-08-13 2010-03-16 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
CN1867560A (zh) 2003-08-13 2006-11-22 武田药品工株式会社 4－嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途
EP1699777B1 (de) 2003-09-08 2012-12-12 Takeda Pharmaceutical Company Limited Dipeptidylpeptidase-hemmer
EP1697342A2 (de) * 2003-09-08 2006-09-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitoren
CN1905876B (zh) 2003-11-17 2010-06-09 诺瓦提斯公司 二肽基肽酶iv抑制剂的用途
EP2165703A3 (de) 2004-01-20 2012-03-28 Novartis Pharma AG Direktkomprimierte Formulierung und Verfahren
US7732446B1 (en) 2004-03-11 2010-06-08 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
WO2005118555A1 (en) 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
GB0412526D0 (en) * 2004-06-05 2004-07-14 Leuven K U Res & Dev Type 2 diabetes
WO2006019965A2 (en) 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
EP1623983A1 (de) * 2004-08-05 2006-02-08 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft Heterozyklische Verbindungen verwendbar als DDP-IV-Inhibitoren
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
NZ566799A (en) 2005-09-14 2011-04-29 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for treating diabetes
WO2007035629A2 (en) 2005-09-16 2007-03-29 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CN101684103B (zh) * 2008-09-22 2011-04-06 天津药物研究院 1,2,4-三唑结构的化合物、其制备方法和用途
EA201791982A1 (ru) 2015-03-09 2020-02-17 Интекрин Терапьютикс, Инк. Способы лечения неалкогольной жировой болезни печени и/или липодистрофии
WO2018162722A1 (en) 2017-03-09 2018-09-13 Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke Dpp-4 inhibitors for use in treating bone fractures
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
CN114014817A (zh) * 2021-12-29 2022-02-08 宁夏常晟药业有限公司 一种均三甲苯基-2-砜基三氮唑的合成方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3308131A (en) * 1962-12-06 1967-03-07 Du Pont Tertiary carbamyl triazoles
WO1992002512A1 (fr) * 1990-08-03 1992-02-20 Chugai Seiyaku Kabushiki Kaisha Compose de triazole
DK0493925T3 (da) * 1990-12-17 1998-07-27 Sankyo Co Pyrazolderivater med herbicid aktivitet, deres fremstilling og anvendelse
US5258361A (en) * 1991-09-27 1993-11-02 Rohm And Haas Company Herbicidal 1-(disubstituted carbamoyl)-3-(N-arylsulfonamido)-1,2,4-triazoles
ZA927272B (en) * 1991-10-29 1994-03-23 Du Pont Herbicidal triazolecarboxamides
US5543396A (en) * 1994-04-28 1996-08-06 Georgia Tech Research Corp. Proline phosphonate derivatives
US5992742A (en) * 1994-08-05 1999-11-30 Sullivan; Scott L. Pill printing and identification
US5737539A (en) * 1994-10-28 1998-04-07 Advanced Health Med-E-Systems Corp. Prescription creation system
US5845255A (en) * 1994-10-28 1998-12-01 Advanced Health Med-E-Systems Corporation Prescription management system
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6915265B1 (en) * 1997-10-29 2005-07-05 Janice Johnson Method and system for consolidating and distributing information
DE19828114A1 (de) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19832017A1 (de) * 1998-07-16 2000-01-27 Hoechst Schering Agrevo Gmbh Herbizide Mittel mit substituierten Phenylsulfonylharnstoffen zur Unkrautbekämpfung in Reis
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US20030080191A1 (en) * 2001-10-26 2003-05-01 Allen Lubow Method and apparatus for applying bar code information to products during production
US7016753B2 (en) * 2001-10-30 2006-03-21 Semiconductor Energy Laboratory Co., Ltd. Management system for production line and management method for production line
US20030140928A1 (en) * 2002-01-29 2003-07-31 Tuan Bui Medical treatment verification system and method
EP1527426A2 (de) * 2002-08-09 2005-05-04 Mckesson Automation Systems, Inc. Sicherheitsschrank zur abgabe von medikamenten, verfahren und system
US6994249B2 (en) * 2003-05-27 2006-02-07 Cardinal Health Technologies, Llc System and method for drug management utilizing transferable labels
US20050033606A1 (en) * 2003-08-06 2005-02-10 Miller Raymond F. Medication order processing and dispensing system
US7801642B2 (en) * 2004-08-18 2010-09-21 Walgreen Co. System and method for checking the accuracy of a prescription fill
US20060054682A1 (en) * 2004-09-07 2006-03-16 Carlos De La Huerga Method and system for tracking and verifying medication
WO2006035417A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
US20070095850A1 (en) * 2005-10-27 2007-05-03 Meyer Daniel D Multiple medication dispensing system

Also Published As

Publication number Publication date
EP1258480B1 (de) 2004-11-10
US20030060494A1 (en) 2003-03-27
EP1258480A1 (de) 2002-11-20
DE60201859T2 (de) 2005-10-20
ES2231609T3 (es) 2005-05-16
US20040186153A1 (en) 2004-09-23
US7238720B2 (en) 2007-07-03

Similar Documents

Publication Publication Date Title
DE60201859D1 (de) Pharmazeutische Verwendung von N-Carbamoylazol-Derivate
ATE395053T1 (de) Pharmazeutische salze von 1-phenyl-3- dimethylamino-propan-verbindungen
DE60223841D1 (de) Medizinische verwendung von gsk3-hemmenden oxindolderivaten
DE60333294D1 (de) Kontrollierte verabreichung von arzneien
ATE370958T1 (de) Phosphonooxy-chinazolin derivate und ihre pharmazeutische verwendung
DE60201988D1 (de) Pharmazeutische dosierungsform von amorphem nilfenavir mesylat
NO20033384L (no) Farmasoytisk formulering
EE200300311A (et) Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim
ATE307571T1 (de) Pharmazeutische formulierung enthaltend bicalutamid
DE60039598D1 (de) Pharmazeutische zusammensetzungen von erythropoietin
DE50212455D1 (de) Verwendung von Dimerdiolen
ATE309789T1 (de) Darreichungsform von ibuprofen-natrium
NO20035627D0 (no) Farmasöytisk formulering
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
EE200300454A (et) Bitsüklilised guanidiini derivaadid ja nende terapeutiline kasutamine
DE10291905D2 (de) Pharmazeutische Zusammensetzung
DK1392670T3 (da) Substituerede C-furan-2-yl-methylamin- og C-thiophen-2-yl-methylamin-derivater
DE60328787D1 (de) Pharmazeutische salze von reboxetin
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
ATA8202001A (de) Medikamentenapplikator
DE60214533D1 (de) Pyridoindolonderivate und antikrebsmittel enthaltende pharmazeutische mischungen
DE50210197D1 (de) Substituierte propan- 1,3-diamin-derivate und ihre pharmazeutische verwendung
DE10107261B4 (de) Pharmazeutische Zusammensetzung
EE200300563A (et) Bensüülaminopürimidiiniühendid, nende kasutamine ja ravim
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKYO, JP